Test Price
550 AED✅ Home Collection Available
C-MYC Immunohistochemistry Test in UAE | Accurate Cancer Prognosis | 550 AED
Executive Summary & Core Metrics
✅ Accuracy Guarantee:
99.9% Diagnostic Sensitivity via ISO Accredited Processing (Cert: INT/EGQ/2509DA/3139).
🚚 Premium Logistics:
Secure Medical Courier Solid Tissue Specimen Retrieval – Specimens are retrieved from the hospital pathology department via certified courier. Home phlebotomy is not applicable for this archival tissue test.
📞 Clinical Guidance:
Telephonic Post-Test Clinical Guidance for result interpretation with our DHA-licensed pathologists.
📱 Insurance:
Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The C-MYC Immunohistochemistry test detects c-MYC oncoprotein overexpression in tumor tissue, providing critical diagnostic and prognostic information for aggressive cancers like lymphomas and breast carcinomas. This assay aids oncologists and pathologists in tailoring targeted therapies and monitoring disease progression.
Methodology: Immunohistochemistry (IHC) using DAB detection on formalin-fixed paraffin-embedded (FFPE) tissue sections. The test measures protein expression levels semi-quantitatively.
| Feature | Our C-MYC IHC Test | c-MYC FISH (Alternative) |
|---|---|---|
| Methodology | Immunohistochemistry (IHC) with DAB detection | Fluorescence In Situ Hybridization (FISH) |
| Precision | High sensitivity for protein levels | Detects gene rearrangements only |
| Turnaround Time | 5–7 days (FFPE block/tissue) | 8–10 days |
| Price | 550 AED | ~1200–1500 AED |
| Clinical Application | Protein overexpression, prognosis, therapy targeting | Gene rearrangement classification |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor | Specialist Diagnostic Radiology | DHA License: 61713011
“As a specialist in diagnostic radiology with expertise in oncologic imaging, I emphasize that c-MYC immunohistochemistry provides valuable prognostic information. A positive result indicates c-MYC protein overexpression, often seen in aggressive lymphomas and breast cancers. However, interpretation must be correlated with full histopathology and imaging findings. Please consult with your oncologist for a personalized treatment plan.”
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Red Flags
- Uncontrolled bleeding disorders or anticoagulant therapy without medical clearance.
- Active skin infection at biopsy site.
- Inability to provide informed consent (minors require guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).
🚨 ER Red Flags:
Seek immediate medical attention if you experience severe pain, excessive bleeding, swelling, or signs of infection (redness, warmth, pus) at the biopsy site, or any systemic symptoms like fever or difficulty breathing post-procedure.
Patient FAQ & Clinical Guidance
1. What is the c-MYC immunohistochemistry test?
This test identifies c-MYC protein overexpression in tumors, informing precise diagnosis and targeted therapy selection. It is used primarily on formalin-fixed paraffin-embedded (FFPE) tissue blocks submitted by your pathologist. It helps oncologists determine the aggressiveness of cancers such as diffuse large B-cell lymphoma and breast carcinoma, guiding treatment with MYC-directed therapies.
2. How should I prepare for the biopsy for c-MYC testing?
Submit complete histopathology report, biopsy site, and clinical history; no other special preparation is needed. The biopsy procedure is performed by your surgeon; our laboratory handles the IHC staining of the submitted tissue. Ensure your doctor sends the specimen in 10% neutral buffered formalin or FFPE block at room temperature.
3. What do c-MYC immunohistochemistry results mean for my treatment?
Positive c-MYC overexpression may indicate aggressive tumor behavior requiring targeted therapies and closer oncological monitoring. A positive result often correlates with high-grade lymphomas or double-hit pathology, prompting consideration for intensive chemotherapy regimens or clinical trials with MYC inhibitors. A negative result suggests lower risk but must be evaluated alongside other markers.
UAE Regulatory & Data Privacy Adherence
This test is performed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient confidentiality and data security are maintained throughout the testing process. The laboratory adheres to DHA guidelines for diagnostic services.
Clinical & Logistical Metadata
| Test Name | C-MYC Immunohistochemistry (IHC) |
| Price (AED) | 550 AED |
| Turnaround Time | 5–7 business days from receipt of specimen |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Unstained Slides. Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Immunohistochemistry (IHC) with DAB detection |
| ICD-10-CM Code | C85.90 (Non-Hodgkin lymphoma, unspecified) or Z85.820 (Personal history of other malignant neoplasm of lymphoid, hematopoietic and related tissue) |
| LOINC Code | 48677-9 (c-MYC protein [Presence] in Tissue by Immunohistochemistry) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians